A novel pyrazolopyridine with in vivo activity in Plasmodium berghei- and Plasmodium falciparum-infected mouse models from structure-activity relationship studies around the core of recently identified antimalarial imidazopyridazines
JavaScript is disabled for your browser. Some features of this site may not work without it.
Please note, we are experiencing high volume submissions; you will receive confirmations of submissions in due course. Data upload (DOI): https://researchdata.up.ac.za/ UPSpace: https://repository.up.ac.za/handle/2263/51914
A novel pyrazolopyridine with in vivo activity in Plasmodium berghei- and Plasmodium falciparum-infected mouse models from structure-activity relationship studies around the core of recently identified antimalarial imidazopyridazines
Toward improving pharmacokinetics, in vivo
efficacy, and selectivity over hERG, structure−activity relationship
studies around the central core of antimalarial imidazopyridazines
were conducted. This study led to the identification
of potent pyrazolopyridines, which showed good in vivo
efficacy and pharmacokinetics profiles. The lead compounds
also proved to be very potent in the parasite liver and
gametocyte stages, which makes them of high interest.